At a glittering award ceremony held on the 13th of June 2017 at Manchester’s Midland Hotel, in the heart of the city, Nanomerics’ was awarded first prize in the Royal Society of Chemistry's Emerging Technologies Competition (Health). The award recognises the commercial and scientific excellence associated with Nanomerics and its MET platform, the technology underpinning Nanomerics’ business.
Latest News and Events
Storm clouds are gathering around pharmaceutical manufactures of opioid prescription pain killers in the US because these drugs are linked to an emerging healthcare crisis. Opiate based pain killers currently remain the 'gold' standard for the treatment of many causes of severe pain due the lack of safe and effective alternatives. This is despite their well known limitations and the high proportion of patients suffering from side effects. Increasingly, the abuse potential of these medicines is seen as a key driver for what FDA Commissioner Dr.
Nanomerics’ Chief Scientific Officer will be presenting on Nanomerics’ Molecular Envelope Technology (MET) at this year’s public outreach event for women scientists - Soapbox Science 2017 London (http://soapboxscience.org/soapbox-science-2017-london/). Soapbox science 2017 London will take place at London’s Southbank on Saturday 27th May from 2pm - 5pm. The event which is organised annually was over subscribed this year with 104 applications chasing 12 speaking slots.
Nanomerics will be presenting data on NM147, the MET-enabled oral form of Amphotericin B, at the 6th World Congress on Leishmaniasis (Worldleish 2017). The conference is organised by the WHO ColIaborating Centre for Leishmaniasis and DNDi and will be held in Toledo, Spain, from 16 to 20 May 2017.
Nanomerics has entered into a development agreement with California based NEMUS Bioscience, Inc. (OTCQB: NMUS), to develop a topical ocular formulation of tetrahydrocannabinol-valine-hemisuccinate (THCVHS), the prodrug of THC, which is the active component of Nemus drug candidate NB1111 being developed for the treatment of glaucoma.
Nanomerics' Ophthalmology SAB Strengthened
Nanomerics today announced that it has licensed the North American rights to NM133 for the treatment of dry eye to IACTA Pharmaceuticals.
At the recent annual International APS PharmSci conference organised by the Academy of Pharmaceutical Sciences, Professor Ijeoma Uchegbu was awarded the Innovative Science Award, sponsored by GSK for her work on translating science into practice.
Nanomerics is pleased to announce a major milestone in toxicology testing of its Molecular Envelope Technology has been completed.